Esperion sues Daiichi Sankyo Europe over $300M milestone; CLEAR Outcomes showed 27% MI reduction

Esperion Therapeutics, Inc.

Complaint seeks declaratory judgment that $300M milestone is triggered by CLEAR Outcomes' 27% nonfatal MI risk reduction.
DSE argues milestone only for MACE-4 composite risk reduction ≥15%; actual MACE-4 was 12.98%.
Esperion stock fell 63% from $3.99 to $1.49 after March 15 disclosure of dispute.
CLEAR Outcomes also showed 23% fatal+nonfatal MI and 15% stroke reduction; milestone tiers are $200M (≥15%) and $300M (≥20%).
Esperion alleges ongoing harm and difficulty raising capital due to DSE's position.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.